WO2004030637A2 - Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive - Google Patents

Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive Download PDF

Info

Publication number
WO2004030637A2
WO2004030637A2 PCT/US2003/009717 US0309717W WO2004030637A2 WO 2004030637 A2 WO2004030637 A2 WO 2004030637A2 US 0309717 W US0309717 W US 0309717W WO 2004030637 A2 WO2004030637 A2 WO 2004030637A2
Authority
WO
WIPO (PCT)
Prior art keywords
6alkyl
pyrazol
aryl
2alkyl
phenyl
Prior art date
Application number
PCT/US2003/009717
Other languages
English (en)
Other versions
WO2004030637A3 (fr
Inventor
Margaret J. Bradbury
Nicholas D. P. Cosford
Mark A. Varney
Jeffery J. Anderson
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/031294 external-priority patent/WO2003029210A2/fr
Priority claimed from PCT/US2002/040147 external-priority patent/WO2003051833A2/fr
Priority claimed from PCT/US2002/041720 external-priority patent/WO2003051315A2/fr
Priority claimed from PCT/US2002/040237 external-priority patent/WO2003053922A2/fr
Priority claimed from PCT/US2002/040486 external-priority patent/WO2003059904A1/fr
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU2003218462A priority Critical patent/AU2003218462A1/en
Publication of WO2004030637A2 publication Critical patent/WO2004030637A2/fr
Publication of WO2004030637A3 publication Critical patent/WO2004030637A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • a major excitatory neurotransmitter in the mammalian nervous system is the glutamate molecule, which binds to neurons, thereby activating cell surface receptors.
  • Such surface receptors are characterized as either ionotropic or metabotropic glutamate receptors.
  • the metabotropic glutamate receptors (“mGluR”) are G protein-coupled receptors that activate intracellular second messenger systems when bound to glutamate. Activation of mGluR results in a variety of cellular responses. In particular, mGluRl and mGluR5 activate phospholipase C, which is followed by mobilizing intracellular calcium.
  • PCT Publication 99/02497 discloses pyridine derivatives useful as mGluR5 mediators.
  • PCT publication WO 02/062323 discloses mGluR5 antagonists as useful for treating pruritic conditions.
  • PCT Publication WO 01/16121 discloses particular heterocyclic compounds as modulators of the metabotropic glutamate receptors useful in treating cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disordes, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retnial degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia, astrocytomas, and the like.
  • Modulators of the mGluR5 receptor are useful in the treatment, prevention and suppression of obesity and obesity related conditions.
  • antagonists and/or inverse agonists of the mGluR5 receptor are useful in the treatment, prevention and suppression of obesity and obesity related conditions.
  • the compounds are also useful for the treatment of eating disorders by inhibiting excessive food intake and the resulting obesity and complications associated therewith.
  • the present invention is concerned with metabotropic glutamate receptor-5 modulators useful in treating, preventing and suppresing obesity and obesity-related conditions, hi particular, antagonists and/or inverse agonists of the mGluR5 receptor are useful in the treatment, prevention and suppression of obesity and obesity related conditions, as well as treating eating disorders by inhibition of excessive food intake and the resulting obesity and complications associated therewith.
  • the mGluR5 antagonists of the general Formula IA are useful in the treatment, prevention and suppression of obesity and obesity related conditions, as well as treating eating disorders by inhibition of excessive food intake and the resulting obesity and complications associated therewith.
  • the invention is also concerned with pharmaceutical formulations comprising an mGluR5 antagonist as defined above together with another agent useful for treating obesity or obesity-related conditions.
  • the present invention is concerned with metabotropic glutamate receptor-5 modulators useful in treating, preventing and suppresing obesity and obesity-related conditions.
  • antagonists and/or inverse agonists of the mGluR5 receptor are useful in the treatment, prevention and suppression of obesity and obesity related conditions, as well as treating eating disorders by inhibition of excessive food intake and the resulting obesity and complications associated therewith.
  • the mGluR5 antagonists of the general Formula IA are useful in the treatment, prevention and suppression of obesity and obesity related conditions, as well as treating eating disorders by inhibition of excessive food intake and the resulting obesity and complications associated therewith.
  • the present invention is concerned with novel substituted amides of the general Formula IA :
  • X a and Ya each independently is aryl or heteroaryl wherein at least one of X and Y a is a heteroaryl with N adjacent to the position of attachment to Aa or B a respectively; X a is optionally substituted with 1-7 independent halogen, -CN, NO2,
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9c ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9sO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5, R6, and R7 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R8 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ba is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOCO-C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOS ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl; R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl -6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl
  • Rl 1, Rl2 and Rl3 are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrrole moiety; wherein the -C ⁇ _6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • any N may be an N-oxide; and wherein any of the alkyl optionally is substituted with 1-9 independent halogens.
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein
  • Rl, R2, and R3 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci -6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C()-6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R4 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C()-6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9c ⁇ -C ⁇ -2alkyl- -C()-2alkyl- NR9s ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5, R ; and R7 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl _6alkyl, -O(CQ-6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • B is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C()-2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-N lOCO-C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlOS ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R and RlO each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C
  • RU, Rl2 and Rl3 are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrrole moiety; wherein the -C ⁇ _6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • any N may be an N-oxide; and wherein any of the alkyl optionally is substituted with 1-9 independent halogens.
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein
  • Rl, R2, and R3 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R4 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Cl _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR 9 CO-C ⁇ -2alkyl- -C()-2alkyl- NR 9 SO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R8 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ -6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(CQ-6 alkyl) (aryl) substituents;
  • Ba is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOCO-C ⁇ -2alkyl
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci -6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • Rl 1, Rl2 and Rl are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrrole moiety; wherein the -Ci_6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C()-6alkyl)(C3_7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) groups; any N may be an N-oxide; and wherein any of the alkyl optionally is substituted with 1-9 independent halogens.
  • the compound of this is substituted
  • Rl, R2, and R3 each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C()-6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6al yl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(Co_ 6alkyl)(aryl) substituents;
  • R4 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR 9 CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR 9 SO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • Y a is 2-pyridyl optionally substituted with 1-4 independent halogen, -
  • R7 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8 is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl
  • B is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOCO-C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlOS ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7 cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein:
  • Rl, R2, and R3 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R4 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Cl-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9c ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9sO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5, R6, and R7 each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 lkyl)(aryl) substituents;
  • Ba is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci -6alkyl, -O(C()-6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • Rl, R2, and R3 each independently is -C()-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci -6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ -
  • R4 is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • Ya is aryl or heteroaryl optionally substituted with 1-7 independent halogen, -CN, NO2, -Ci -6alkyl, -C ⁇ _6alkenyl, -C ⁇ _6alkynyl, -OR5, -NR5R6,
  • R5, R6, and R7 each independently is -C()-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci -6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ba is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein:
  • Rl, R2, and R each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl_6alkyl, -O(C()-6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4 is -Ci- ⁇ alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C()-2alkyl-S ⁇ 2-C ⁇ -
  • Y a is 2-pyridyl optionally substituted with 1-4 independent halogen, -
  • R5, R6, and R7 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ - ⁇ alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C -7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8 is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • B is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • Rl, R2, and R3 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci -6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R8 is -Ci. ⁇ alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3- 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ba is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein
  • Rl, R2, and R3 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ -
  • R4 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5, R6 ; and R7 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8 is -Ci-6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein:
  • Rl, R2, and R3 each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9c ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9s ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • Y is pyrazolyl optionally substituted with 1-3 independent halogen, -
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • Rll, Rl2 and Rl3 are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrrole moiety; wherein the -Ci_6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), or -N(Co-6alkyl)(aryl) groups; any N may be an N-oxide; and wherein any of the alkyl optionally is substituted with 1-9 independent halogens.
  • Rl, R2, and R3 each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl -6alkyl, -O(CQ-6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R4 is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Aa is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9sO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • Y a is pyrazolyl optionally substituted with 1-2 independent halogen, -
  • Ba is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOCO-C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9 and RlO each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(CQ-6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • Y a is phenyl optionally substituted with 1-5 independent halogen, - CN, NO2, -C ⁇ _6alkyl, -C ⁇ _6alkenyl, -C ⁇ _6alkynyl, -ORl, -NR1R2, -
  • Y a is 2-pyridyl optionally substituted with 1-4 independent halogen, -CN, NO 2 , -C ⁇ _6alkyl, -C ⁇ _6alkenyl, -C ⁇ _6alkynyl, -ORl, -NR1R2, -
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein: X a is pyridyl optionally substituted with 1-4 independent halogen, -
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein: X a is phenyl optionally substituted with 1-5 independent halogen, -
  • the compound of this invention is represented by Formula (IA) or a pharmaceutically acceptable salt thereof, wherein: Y a is pyrazolyl optionally substituted with 1-3 independent halogen, -
  • Rib, R2b 5 and R3b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b ; R6b, and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b ; and R3b each independently is -C ⁇ -6alkyl, -C3-.
  • R4b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5b, R6b and R7b each independently is -C ⁇ -6alkyl, -C3_ 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 .
  • ⁇ b is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • Rib, R2b ; and R3b each independently is -C ⁇ -6 a lkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b s -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR 9 SO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b R6b, and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C 0 -6alkyl)(C 0 -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b i s -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • ⁇ b is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOCO-C ⁇ -2
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), -N(C 0 - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b i s each independently halogen, -C ⁇ -6alkyl, -C ⁇ -
  • Rl lband Rl2b are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrazole moiety; wherein the -C ⁇ _6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9c ⁇ -C ⁇ -2alkyl- -C ⁇ -2alkyl- NR9sO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b R6b and R7b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents; ⁇ b is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b i s each independently halogen, -C ⁇ -6 a lkyl, -C ⁇ - ⁇ alkoxyl, or -N(C ⁇ -4alkyl)(C
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein
  • Rib, R2b and R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3-7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl l and Rl2b is each independently halogen, -C ⁇ -6 a lkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b ; and R3b each independently is -C ⁇ -6 a lkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 _ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b and R7b each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b nd RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3.7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b i s each independently halogen, -C ⁇ -6alkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b R6b, and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents; ⁇ b is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2al
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b i s each independently halogen, -C ⁇ -6alkyl, -C ⁇ - ⁇ alkoxyl, or -N(C ⁇ -4alkyl)(C ⁇ -4alkyl
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b i s -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3- 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 _ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, an d R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C 0 -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b is each independently halogen, -C ⁇ -6 a lkyl, -C ⁇ - ⁇ alkoxyl, or -N(C ⁇ -4alkyl)
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3- 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6 lkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b is each independently halogen, -C ⁇ -6alkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -Ci- ⁇ alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C ⁇ -6alkyl)(C 3 - 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -C ⁇ -6 a lkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-N lObc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlObsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C 0 -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b i s each independently halogen, -C ⁇ -6 a lkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -Co_2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b i s N, the other is CRl2b ; Rl lb and Rl2b is each independently halogen, -C ⁇ -6 a lkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(ary
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b and R7b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -
  • R8b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlObsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb ea ch independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6al
  • Rl lb and Rl2b i s each independently halogen, -C ⁇ -6 a lkyl, -C ⁇ - 6alkoxyl, or -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), wherein optionally Rllb and Rl2b are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrazole moiety; wherein the -Ci-galkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -Cl-6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloal
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3-7cycloalkyl), -N(Q)- 6alkyl)(aryl) substituents; one of Alb an d A b i s N, the other is CRl2b ;
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • R4b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -Co ⁇ 6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • R8b is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents; ⁇ b is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl-
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-.
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_
  • Ab is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • Yb is quinolinyl optionally substituted with 1-6 independent halogen, - CN, NO2, -C ⁇ _6alkyl, -Ci-6alkenyl, -C ⁇ _6alkynyl, -OR5b, -NR5bR6b,
  • R8b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(ary
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(Co-6alkyl)(Co-6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlObsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb an d A2b i s N, the other is CRl2b;
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-
  • R4b is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • Yb is pyrazolyl optionally substituted with 1-3 independent halogen, - CN, NO2, -Ci_6alkyl, -Ci-6alkenyl, -C ⁇ _6alkynyl, -OR5b, -NR5bR6b,
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6al yl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bb is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), -
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3-
  • R4b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-galkyl, -O(C ⁇ -6alkyl), -O(C3_
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ -
  • Yb is pyrazolyl optionally substituted with 1-3 independent halogen, - CN, NO2, -Ci-6alkyl, -C ⁇ _6alkenyl, -C ⁇ _6alkynyl, -OR5b, -NR5bR6b,
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7 cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents; ⁇ b is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alky
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; one of Alb and A2b is N, the other is CRl2b;
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, and R3b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -Ci- ⁇ alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5b, R6b, and R7b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Bb is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlObc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlObs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alky
  • Rib, R2b and R3b each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -Ci_6alkyl, -C3-7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C 3 - 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ab is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9bc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR9bsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R8b is -Ci. ⁇ alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Cl_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -Ci. ⁇ alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Cl_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IB) or a pharmaceutically acceptable salt thereof, wherein:
  • Rib, R2b, an d R3b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4b is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ab is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5b, R6b, and R7b each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8b is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -
  • R9b and RlOb each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • a compound of this invention is represented by Formula (IC):
  • Xc and Yc each independently is aryl or heteroaryl wherein at least one of X c and Y c is a heteroaryl with N adjacent to the position of attachment to Ac or B c respectively; three of Ale, A2C, A 3 C, A c, and A5c are N, the remaining are C, and one of Ale and A4c mU st be N, but not both Ale and A4c are N;
  • Rlc, R2c, and R3c each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent , halogen, -CN, -C l-6alkyl, -O(Co_6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4c is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • Ac is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • Y c is optionally substituted with 1-7 independent halogen, -CN, NO2,
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOcc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOcsO2-Co-2alkyl-, or -heteroC ⁇ -4alkyl;
  • R9c and RlOc each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C 0 - 6alkyl)(aryl) substituents;
  • the compound of this invention is represented by Formula (IC) or a pharmaceutically acceptable salt thereof, wherein
  • Rlc, R2c, and R c each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4c is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • Ac is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5C, R6C, and R7c each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8c is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents; ⁇ c is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlOcc ⁇ -C ⁇ -2alkyl
  • the compound of this invention is represented by Formula (IC) or a pharmaceutically acceptable salt thereof, wherein
  • R5C, R6C, and R7c each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7 cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8c is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Be is -Co_4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-N lOcCO-C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOcs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9c and RlOc each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(CQ-6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any alkyl optionally substituted with 1-5 independent halogen substitutents, and any N may be an N-oxide.
  • the compound of this invention is represented by Formula (IC) or a pharmaceutically acceptable salt thereof, wherein:
  • Rlc, R2C, and R3c each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4c is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-
  • Ac is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5C, R6C, and R7c each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8c is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOcc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOcs ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9c and RlOc each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any alkyl optionally substituted with 1-5 independent halogen substitutents, and any N may be an N-oxide.
  • the compound of this invention is represented by Formula (IC) or a pharmaceutically acceptable salt thereof, wherein
  • Xd and Y each independently is aryl or heteroaryl wherein at least one of X and Y is a heteroaryl with N adjacent to the position of attachment to A or ⁇ respectively;
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • R8d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • B is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlO ea ch independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein
  • R4d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-galkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C 0 -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bd is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3 each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -Ci- ⁇ alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(CQ-6alkyl)(aryl) substituents; Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-
  • Y is phenyl optionally substituted with 1-5 independent halogen, - CN, NO2, -C ⁇ _6alkyl, -C ⁇ _6alkenyl, -C ⁇ _6alkynyl, -OR5d, _NR5dR6d,
  • R8d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 _ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bd is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlds ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3..
  • A is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R8d is -C _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6 a lkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), -
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein
  • Rid, R2d, a d R3d each independently is -C ⁇ -6alkyl, -C3_ 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(CQ-6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(Co-6alkyl)(aryl) substituents;
  • R4d is -C ⁇ _6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 alkyl) (aryl) substituents;
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRldS ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, Rod, and R7d each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 alkyl) (aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(Q)- 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3. 7 cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRl d S ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • R8d is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(Q)_6a]kyl)(C3- 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlds ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlds ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3..
  • R8d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents; ⁇ d is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRl dc ⁇ -C ⁇ -2alkyl
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), -N(C 0 - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3- 7cycloalkyl), -N(CQ-6alkyl)(aryl) substituents; Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlds ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3-
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-galkyl, -O(C ⁇ -6alkyl), -O(C3_
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R8d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl), -O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 - 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • B is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), -
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(CQ-6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3.7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -C ⁇ _6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlds ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d R6d, and R7d each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d s -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • the compounds of this invention are represented by Formula (ED) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 _7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NR 1 s ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl ;
  • R5d, R6d, a nd R7d each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • R8d is -C ⁇ _6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • R4 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6 a lkyl)(aryl) substituents;
  • R4 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, R6d, and R7d each independently is -C ⁇ -6 lkyl, -C3-
  • R ⁇ d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(CQ-6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents; ⁇ d is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, a nd R3d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2al
  • R8 is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8 is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7 cycloalkyl), -O(aryl),
  • B is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3_
  • R4d is -Ci- ⁇ alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d is -Ci_6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), -
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(Co-6alkyl)(aryl) substituents;
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3.
  • R8d is -Ci-galkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6alkyl), -O(C3_
  • B is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Ad is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlds ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d R6d, and R7d ea ch independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • B d is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2 ⁇ C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRldsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(Co ⁇ 6alkyl)(aryl) substituents;
  • R4 is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • a d is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRl d S ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3-.
  • R4d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • B d is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldsO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cyclo alkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6 alkyl) (aryl) substituents; and any N may be an N-oxide.
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, R6d, a nd R7d eac h independently is -Co_6alkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -
  • R8d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-N ldCO-C ⁇ -2alkyl-, -Co_ 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • R4d is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents; Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5d, R6d, and R7d each independently is -C ⁇ -6alkyl, -C3. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Cl_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • ⁇ d is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -Co_2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7 cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3d each independently is -C ⁇ -6alkyl, -C3-. 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R4d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • A is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2
  • R8 is -Ci_6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C ⁇ -6alkyl)(aryl) substituents;
  • R8 is -Ci_6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3- 7cycloalkyl), -O(aryl),
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOdc ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • Rid, R2d, a nd R3d each independently is -C ⁇ -6alkyl, -C3.
  • R4d is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R8d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C 0 -6alkyl), -N(C 0 -6alkyl)(C3- 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Bd is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compounds of this invention are represented by Formula (ID) or a pharmaceutically acceptable salt thereof, wherein:
  • Rid, R2d, and R3d each independently is -C ⁇ -6 a lkyl, -C3- 7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), - O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), - N(C0-6 a lkyl)(aryl) substituents;
  • R4d is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(Co-6alkyl)(C3_ 7cycloalkyl), -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ad is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9dc ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRldSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5d, Rod, and R7d each independently is -C ⁇ -6alkyl, -C3-
  • R8d is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_
  • ⁇ d is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9d and RlOd each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents; and any N may be an N-oxide.
  • a compound of this invention is represented by Formula (IE):
  • Xc and Y e each independently is aryl or heteroaryl wherein at least one of X e and Y e is a heteroaryl with N adjacent to the position of attachment to A e or B e respectively;
  • Rle, R2e, and R3e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), or -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R4e is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9ec ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9esO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • R5e, R6e, and R7e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), or -N(Q)- 6alkyl)(aryl) substituents;
  • R8e is -C ⁇ _6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), or -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9e and RlOe each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • the compound of this invention is represented by Formula (IE) or a pharmaceutically acceptable salt thereof, wherei
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9ec ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9es ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5e, R6e, and R7e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci_6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R8e is -Ci- ⁇ alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3- 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9e and RlOe each independently is -C ⁇ -6 lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C 0 -6alkyl)(C3-7cycloalkyl), -N(C 0 - 6alkyl)(aryl) substituents; Rl le and Rl2e i s each independently halogen, -C ⁇ -6alkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IE) or a pharmaceutically acceptable salt thereof, wherein:
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9ec ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9es ⁇ 2-C ⁇ -2alkyl- or -heteroC ⁇ -4alkyl;
  • R5e, R6e, and R7e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), or -N(C ⁇ - 6alkyl)(aryl) substituents;
  • R8e is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), or -N(C ⁇ -6 a lkyl)(aryl) substituents;
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOec ⁇ -C ⁇ -2alkyl- -C ⁇ - 2alkyl-NRlOesO2-Co-2alkyl-, or -heteroC ⁇ -4alkyl;
  • R9e and RlOe each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3-7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • Ye is not 3-cyanophenyl.
  • the compound of this invention is represented by Formula (IE) or a pharmaceutically acceptable salt thereof, wherein: X e is 2-pyridyl optionally substituted with 1-4 independent halogen, -
  • Rle, R2e, a nd R3e each independently is -C ⁇ -6alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4e is -Ci-6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6 a lkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl- -C ⁇ -2alkyl-NR9ec ⁇ -C ⁇ -2alkyl-, -C ⁇ -2alkyl- NR9esO2-Co-2alkyl- or -heteroC ⁇ -4alkyl;
  • Y e is pyridyl optionally substituted with 1-4 independent halogen, -
  • R5e, R6e, and R7e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C 0 -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C 3 -7cycloalkyl), or-N(Q)- 6alkyl)(aryl) substituents;
  • R8e is -Ci- ⁇ alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) substituents;
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOec ⁇ -C ⁇ -2al
  • R9e and RlOe each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • Rle, R2e, and R3e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), or -N( )- 6alkyl)(aryl) substituents;
  • R4e is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) substituents;
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl- -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl-, -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NR9ec ⁇ -C ⁇ -2al
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOec ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOesO2-Co-2alkyl-, or -heteroC ⁇ -4alkyl;
  • R9e and RlOe each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci-6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), -N(C ⁇ - 6alkyl)(aryl) substituents;
  • Xe is not 3-cyanophenyl.
  • the compound of this invention is represented by
  • Rle, R2e, and R3e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4e is -Ci_6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O (heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R5e, R6e, a nd R7e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3-7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), or -N(Q)- 6 a lkyl)(aryl) substituents;
  • R8e is -Ci- ⁇ alkyl, -C3-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6al yl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3- 7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) substituents;
  • Be is -C ⁇ -4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • R9e and RlOe each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), -
  • Rl le and Rl2e is each independently halogen, -C ⁇ -6alkyl, -C ⁇ -
  • the compound of this invention is represented by Formula (IE) or a pharmaceutically acceptable salt thereof, wherein
  • Rle, R2e, and R3e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -Ci- ⁇ alkyl, -O(C ⁇ -6al yl), -O(C3_7cycloalkyl), -O(aryl), -
  • R4e is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_
  • Ae is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ -
  • NR9eSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl NR9eSO2-Co-2alkyl- or -heteroC ⁇ -4alkyl
  • Y e is 2-pyridyl optionally substituted with 1-4 independent halogen, -
  • R5e, R6e, and R7e each independently is -C ⁇ -6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(CQ-6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_7cycloalkyl), or-N(Q)- 6alkyl)(aryl) substituents;
  • R8e is -C ⁇ _6alkyl, -C3_7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_ 7cycloalkyl), -O(aryl), -O(heteroaryl), -N(C ⁇ -6alkyl)(C ⁇ -6alkyl), -N(C ⁇ -6alkyl)(C3_ 7cycloalkyl), or -N(C ⁇ -6alkyl)(aryl) substituents;
  • Be is -Co-4alkyl, -C ⁇ -2alkyl-SO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-S ⁇ 2-C ⁇ - 2alkyl- -C ⁇ -2alkyl-CO-C ⁇ -2alkyl-, -C ⁇ -2alkyl-NRlOec ⁇ -C ⁇ -2alkyl-, -C ⁇ - 2alkyl-NRlOesO2-Co-2alkyl-, or -heteroC ⁇ -4alkyl;
  • R9e and RlOe each independently is -C ⁇ -6 a lkyl, -C3_7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C ⁇ _6alkyl, -O(C ⁇ -6alkyl), -O(C3_7cycloalkyl), -O(aryl), - O(heteroaryl), -N(C ⁇ -6
  • a compound of this invention is represented by Formula (IF):
  • Yf is O, or N-R4f; one of Zl, Z2 , z3 or Z optionally is N, or NH; Rlf is -OH, halogen, or -CN; or a -Ci_6alkyl, -C ⁇ _4alkoxyl, - cycloC3_6alkyl, -C ⁇ -4alkyl-phenyl, -C ⁇ -4alkyl-pyridyl, -C ⁇ -4alkyl-imidazolyl, - C ⁇ -4alkyl-pyrazolyl, -C ⁇ -4alkyl-triazolyl, -C ⁇ -4alkyl-tetrazolyl, -CQ-4alkyl- dioxolanyl, -C ⁇ -4alkyl-thiazolyl, -C ⁇ -4alkyl-piperidinyl, -C ⁇ -4alkyl-pyrrolidinyl, - C ⁇ -4alkyl-morpholinyl,
  • R2f is hydrogen, halogen, -OH, -CN, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), - NO2; or -Ci_6alkyl, -C ⁇ _4alkoxyl, -C ⁇ -4alkyl-phenyl, or-C ⁇ _4alkoxy-phenyl group, wherein any of the groups is optionally substituted with 1-3 independently halogen, -OH, -CN, or -Ci-4alkoxyl substituents;
  • R3f is hydrogen or -Ci-4alkoxyl
  • R4f is -Co-4alkyl
  • R5f is H, halogen, or -C ⁇ _4alkyl.
  • the compound of this invention is represented by Formula (IE) or a pharmaceutically acceptable salt thereof, wherein
  • Zl, Z2 z3, and Z4 are each CH;
  • Xf is N
  • Yf is O
  • Rlf is -OH, halogen, or -CN; or a -C ⁇ _6alkyl, -Ci_4alkoxyl, - cycloC3-6alkyl, -C ⁇ -4alkyl-phenyl, -C ⁇ -4alkyl-pyridyl, -C ⁇ -4alkyl-imidazolyl, - C ⁇ -4alkyl-pyrazolyl, -C ⁇ -4alkyl-triazolyl, -C ⁇ -4alkyl-tetrazolyl, -C ⁇ -4alkyl- dioxolanyl, -C ⁇ -4alkyl-thiazolyl, -C ⁇ -4alkyl-piperidinyl, -C ⁇ -4alkyl-pyrrolidinyl, - C ⁇ -4alkyl-morpholinyl, -C ⁇ -4alkyl-pyrimidinyl, -C2-6 a lkynyl-thiazolyl, or -N(
  • R2f is hydrogen, halogen, -OH, -CN, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), - NO2; or -Ci_6alkyl, -C ⁇ _4alkoxyl, -C ⁇ -4alkyl-phenyl, or -C ⁇ _4alkoxy-phenyl group, wherein any of the groups is optionally substituted with 1-3 independently halogen, -OH, -CN, or -C ⁇ _4alkoxyl substituents; R3f is hydrogen or -Ci-4alkoxyl; R4f is -Co-4alkyl; and R5f is H, halogen, or -C ⁇ _4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein:
  • Zl, Z2, Z3, and Z are each CH;
  • Xf is N; Yf is O;
  • Rlf is -Ci- ⁇ alkyl, optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -Ci-6alkyl, -C ⁇ _ 4alkoxyl, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -C ⁇ -4alkyl-C(O)-O-C ⁇ -4alkyl, -C ⁇ -4alkyl- morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl; R2f is hydrogen, halogen, -OH, -CN, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -
  • R5f is H, halogen, or-C ⁇ _4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein: Zl, Z2, Z3, and Z4 are each CH;
  • Xf is N; Yf is O;
  • Rlf is -C ⁇ _6alkyl, optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -Ci-6alkyl, -C ⁇ _ 4alkoxyl, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -C ⁇ -4alkyl-C(O)-O-C ⁇ -4alkyl, -C ⁇ -4alkyl- morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is -C ⁇ -4alkyl-phenyl optionally substituted with 1-3 independently halogen, -OH, -CN, or -C ⁇ _4alkoxyl substituents;
  • R3f is hydrogen or -Ci-4alkoxyl;
  • R4f is -Co-4alkyl;
  • R5f is H, halogen, or -Ci-4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein: Zl, Z2, Z3, and Z4 are each CH; Xf is N;
  • Yf is O
  • Rlf is -Ci-galkyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -C ⁇ _6alkyl, -C ⁇ _4alkoxyl, - N(Co-4alkyl)(Co-4alkyl), -C ⁇ -4alkyl-C(O)-O-C ⁇ -4alkyl, -C ⁇ -4alkyl-morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is hydrogen; or-Ci-6alkyl optionally substituted with 1-3 independently halogen, -OH, -CN, or-Ci_4alkoxyl substituents;
  • R3f is hydrogen or -C ⁇ _4alkoxyl; R4f is -Co-4alkyl; and
  • R5f is H, halogen, or -Ci-4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein: Zl , Z2, Z3, and Z are each CH;
  • Xf is N
  • Yf is O
  • Rlf is -C ⁇ _6alkyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -Ci- ⁇ alkyl, -Ci-4-dkoxyl, - N(Co-4alkyl)(Co-4alkyl), -C ⁇ -4alkyl-C(O)-O-C ⁇ -4alkyl, -C ⁇ -4alkyl-morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is or -NO2; or -N(C ⁇ -4alkyl)(C ⁇ -4alkyl) optionally substituted with 1-3 independently halogen, -OH, -CN, or-C ⁇ _4alkoxyl substituents;
  • R3f is hydrogen or -C ⁇ _4alkoxyl; R4f is -Co-4alkyl; and
  • R5f is H, halogen, or -Ci_4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein: Zl, Z2, z3, and Z4 are each CH;
  • Xf is N
  • Yf is O
  • Rlf is -C _6alkyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -C ⁇ _6alkyl, -Ci-4alkoxyl, - N(Co-4alkyl)(Co-4alkyl), -Co-4alkyl-C(O)-O-Co-4alkyl, -Co-4alkyl-morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is -C ⁇ _4alkoxy-phenyl optionally substituted with 1-3 independently halogen, -OH, -CN, or -Ci-4alkoxyl substituents; R f is hydrogen or -C ⁇ _4alkoxyl;
  • R4f is -Co-4alkyl
  • R5f is H, halogen, or-C ⁇ _4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein:
  • Zl, Z2, Z3, and Z4 are each CH;
  • Xf is N
  • Yf is O
  • Rlf is -C ⁇ _6alkyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -Ci-6alkyl, -C ⁇ _4alkoxyl, - N(Co-4alkyl)(Co-4alkyl), -Co-4alkyl-C(O)-O-Co-4alkyl, -Co-4alkyl-morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is -C ⁇ _4alkoxyl optionally substituted with 1-3 independently halogen, -OH, -CN, or -C ⁇ _4alkoxyl substituents;
  • R3f is hydrogen or -C ⁇ _4alkoxyl ;
  • R4f is -Co-4alkyl
  • R5f is H, halogen, or -C ⁇ _4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein:
  • Zl, Z2, Z3, and Z4 are each CH;
  • Xf is N
  • Yf is O
  • Rlf is -cycloC3_6alkyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -Ci_6alkyl, -Ci- 4alkoxyl, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -C ⁇ -4alkyl-C(O)-O-C ⁇ -4alkyl, -C ⁇ -4alkyl- morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is halogen, -OH, -CN, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -NO2; or -C ⁇ _ 6alkyl, -Ci_4alkoxyl, -CQ-4alkyl-phenyl, or -C ⁇ _4alkoxy-phenyl group, wherein any of the groups is optionally substituted with 1-3 independently halogen, -OH, - CN, or-C ⁇ _4alkoxyl substituents;
  • R3f is hydrogen or-C ⁇ _4alkoxyl
  • R4f is -Co-4alkyl
  • R5f is H, halogen, or -Ci-4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein:
  • Zl, Z2, Z3, and Z4 are each CH; Xf is N;
  • Yf is O
  • Rlf is -C ⁇ -4alkyl-triazolyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, -OH, -CN, -Ci- 6alkyl, -C ⁇ _4alkoxyl, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -C ⁇ -4alkyl-C(O)-O-C ⁇ -4alkyl, - C ⁇ -4alkyl-morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is halogen, -OH, -CN, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -NO2; or -Cl- 6alkyl, -C ⁇ _4alkoxyl, -C ⁇ -4alkyl-phenyl, or -C ⁇ _4alkoxy-phenyl group, wherein any of the groups is optionally substituted with 1-3 independently halogen, -OH, - CN, or -C ⁇ _4alkoxyl substituents; R3f is hydrogen or -C ⁇ _4alkoxyl;
  • R4f is -Co-4alkyl
  • R5f is H, halogen, or -C ⁇ _4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein:
  • Zl, Z2, Z3, and Z4 are each CH;
  • Xf is N
  • Yf is O
  • Rlf is -C ⁇ -4alkyl-imidazolyl or -C ⁇ -4alkyl-pyrazolyl optionally substituted with 1-5 substituents; wherein each substituent is independently halogen, - OH, -CN, -Ci-6alkyl, -Ci-4alkoxyl, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -C ⁇ -4alkyl-C(O)- O-C ⁇ -4alkyl, -C ⁇ -4alkyl-morpholinyl, or -C ⁇ -4alkyl-benzoxazolyl;
  • R2f is halogen, -OH, -CN, -N(C ⁇ -4alkyl)(C ⁇ -4alkyl), -NO2; or -C ⁇ _ 6alkyl, -Ci_4alkoxyl, -CQ-4alkyl-phenyl, or -C ⁇ _4alkoxy-phenyl group, wherein any of the groups is optionally substituted with 1-3 independently halogen, -OH, - CN, or-Ci_4alkoxyl substituents;
  • R3f is hydrogen or-Ci-4alkoxyl
  • R4f is -C ⁇ -4alkyl
  • R5 is H, halogen, or -C l -4alkyl.
  • the compound of this invention is represented by Formula (IF) or a pharmaceutically acceptable salt thereof, wherein:
  • Zl, Z2, Z3, and Z are each CH; Xf is N;
  • Yf is O

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des modulateurs des récepteurs 5 métabotropiques du glutamate (mGluR5) utiles pour traiter des troubles associés à une consommation alimentaire excessive, y compris l'obésité et les troubles associés à l'obésité. Plus particulièrement, l'invention concerne les antagonistes des mGluR5 représentés par les formules IA-IF, lesquels sont utiles pour traiter de telles affections soit en tant qu'agents uniques, soit en combinaison avec d'autres composés utilisés pour le traitement de l'obésité.
PCT/US2003/009717 2002-10-01 2003-03-31 Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive WO2004030637A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003218462A AU2003218462A1 (en) 2002-10-01 2003-03-31 Treatment of obesity and other disorders associated with excessive food intake

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
USPCT/US02/31294 2002-10-01
PCT/US2002/031294 WO2003029210A2 (fr) 2001-10-04 2002-10-01 Composes de tetrazole substitues par heteroaryle, modulateurs du recepteur-5 metabotropique du glutamate
PCT/US2002/040147 WO2003051833A2 (fr) 2001-12-18 2002-12-13 Modulateurs pyrazole a substitution heteroaryle du recepteur 5 metabotropique de glutamate
USPCT/US02/41720 2002-12-13
PCT/US2002/041720 WO2003051315A2 (fr) 2001-12-18 2002-12-13 Modulateurs triazole substitues par heteroaryle du recepteur metabotropique 5 du glutamate
USPCT/US02/40147 2002-12-13
USPCT/US02/40237 2002-12-16
PCT/US2002/040237 WO2003053922A2 (fr) 2001-12-19 2002-12-16 Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5
PCT/US2002/040486 WO2003059904A1 (fr) 2001-12-21 2002-12-17 Modulateurs pyrrole a substitution heteroaryle du recepteur 5 metabotropique du glutamate
USPCT/US02/40486 2002-12-17

Publications (2)

Publication Number Publication Date
WO2004030637A2 true WO2004030637A2 (fr) 2004-04-15
WO2004030637A3 WO2004030637A3 (fr) 2004-09-23

Family

ID=32074735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009717 WO2004030637A2 (fr) 2002-10-01 2003-03-31 Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive

Country Status (2)

Country Link
AU (1) AU2003218462A1 (fr)
WO (1) WO2004030637A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071730A1 (fr) * 2004-12-27 2006-07-06 Astrazeneca Ab Composes de pyrazolone utilises comme agonistes du recepteur de glutamate metabotropique pour le traitement de troubles neurologiques et psychiatriques
WO2011073297A1 (fr) * 2009-12-18 2011-06-23 Neurosearch A/S Dérivés du tétrazole en tant que modulateurs des récepteurs nicotiniques de l'acétylcholine
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
PL442982A1 (pl) * 2022-11-29 2024-06-03 Uniwersytet Medyczny W Lublinie N-podstawione pochodne 1-(1-fenylo-3-arylo)-1H-pirazol-4-ylo)metanaminy, sposób ich wytwarzania i ich zastosowanie
US12006332B2 (en) 2019-06-17 2024-06-11 Hibercell, Inc. Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [Online] 03 January 2001 REIMANN E. ET AL: 'Intramolecular alkylation of aromatic compounds. Part XXXIV. Synthesis of (pyridinylmethyl)indoles as potential precursors of ergolines', XP002981277 Database accession no. (ACC178709) & PHAMAZIE vol. 55, no. 12, 2000, pages 907 - 912, XP002903667 *
KOST ET AL: 'Reactions of Hydrazine Derivatives' OBSHCH. KHIM. vol. 33, no. 11, 1963, pages 3603 - 3613, XP002981296 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071730A1 (fr) * 2004-12-27 2006-07-06 Astrazeneca Ab Composes de pyrazolone utilises comme agonistes du recepteur de glutamate metabotropique pour le traitement de troubles neurologiques et psychiatriques
WO2011073297A1 (fr) * 2009-12-18 2011-06-23 Neurosearch A/S Dérivés du tétrazole en tant que modulateurs des récepteurs nicotiniques de l'acétylcholine
US10995078B2 (en) 2013-03-13 2021-05-04 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10472342B2 (en) 2013-03-13 2019-11-12 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10800750B2 (en) 2013-03-13 2020-10-13 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10363224B2 (en) 2013-03-13 2019-07-30 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10450286B2 (en) 2013-03-13 2019-10-22 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10457655B2 (en) 2013-03-13 2019-10-29 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10172878B2 (en) 2013-03-15 2019-01-08 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11267805B2 (en) 2018-10-29 2022-03-08 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
US12006332B2 (en) 2019-06-17 2024-06-11 Hibercell, Inc. Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
PL442982A1 (pl) * 2022-11-29 2024-06-03 Uniwersytet Medyczny W Lublinie N-podstawione pochodne 1-(1-fenylo-3-arylo)-1H-pirazol-4-ylo)metanaminy, sposób ich wytwarzania i ich zastosowanie

Also Published As

Publication number Publication date
WO2004030637A3 (fr) 2004-09-23
AU2003218462A8 (en) 2004-04-23
AU2003218462A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
RU2470021C2 (ru) Пиридилпиперидиновые антагонисты рецептора орексинов
US9745284B2 (en) 2-pyridyloxy-4-ether orexin receptor antagonists
US9586934B2 (en) 2-pyridyloxy-4-methyl orexin receptor antagonists
US9987255B2 (en) 5,5-bicyclic oxazole orexin receptor antagonists
EP1434773B1 (fr) Composes de tetrazole substitues par heteroaryle, modulateurs du recepteur-5 metabotropique du glutamate
US9920038B2 (en) Methyl oxazole orexin receptor antagonists
US9550786B2 (en) 4-fluoropiperidine orexin receptor antagonists
US8003797B2 (en) Pyridine carboxamide orexin receptor antagonists
US9725434B2 (en) Hydroxy-substituted orexin receptor antagonists
US8940898B2 (en) Piperidinyl alkyne orexin receptor antagonists
US10435398B2 (en) Oxazole orexin receptor antagonists
EP3030233B1 (fr) Antagonistes de récepteur d'orexine à base d'oxazole
US10010539B2 (en) Pyrazole, triazole and tetrazole orexin receptor antagonists
AU2002341921A1 (en) Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
EP4010314B1 (fr) Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
WO2003048137A1 (fr) Modulateurs du recepteur metabotropique 5 du glutamate
US20160068514A1 (en) Halo and trifluoromethyl substituted orexin receptor antagonists
WO2008008286A2 (fr) Pyrazoles substitués servant d'antagonistes des récepteurs de la ghréline
WO2022119888A1 (fr) Agonistes 3-hétéroaryl pyrrolidine et pipéridine des récepteurs de l'orexine
WO2004030637A2 (fr) Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP